566
Views
0
CrossRef citations to date
0
Altmetric
Research Article

GWAS Replication Study Confirms the Association of PDE3A–SLCO1C1 with anti-TNF Therapy Response in Rheumatoid Arthritis

, , , , , , , , , , , , , , , , , & show all
Pages 727-734 | Published online: 08 May 2013

References

  • Lipsky PE , van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med.343 , 1594–1602 (2000).
  • Strand V , KimberlyR, IsaacsJD. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov.6 , 75–92 (2007).
  • Marsal S , JuliaA. Rheumatoid arthritis pharmacogenomics. Pharmacogenomics11 , 617–619 (2010).
  • Liu C , BatliwallaF, LiW et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14 , 575–581 (2008).
  • Suarez-Gestal M , Perez-PampinE, CalazaM, Gomez-ReinoJJ, GonzalezA. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res. Ther.12 , R72 (2010).
  • Krintel SB , PalermoG, JohansenJS et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFα inhibitors in patients with rheumatoid arthritis. Pharmacogenet. Genomics 22 , 577–589 (2012).
  • Plant D , BowesJ, PotterC et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 63 , 645–653 (2011).
  • Arnett FC , EdworthySM, BlochDA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31 , 315–324 (1988).
  • van Gestel AM , HaagsmaCJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum.41 , 1845–1850 (1998).
  • So HC , GuiAH, ChernySS, ShamPC. Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genet. Epidemiol.35 , 310–317 (2011).
  • Obaidat A , RothM, HagenbuchB. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu. Rev. Pharmacol. Toxicol.52 , 135–151 (2012).
  • Hagenbuch B , GuiC. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica38 , 778–801 (2008).
  • Essayan DM . Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol.108 , 671–680 (2001).
  • Shenoy P , AgarwalV. Phosphodiesterase inhibitors in the management of autoimmune disease. Autoimmun. Rev.9 , 511–515 (2010).
  • Prabhakar U , LipshutzD, BartusJO et al. Characterization of cAMP-dependent inhibition of LPS-induced TNF α production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16 , 805–816 (1994).
  • Co MS , QueenC. Humanized antibodies for therapy. Nature351 , 501–502 (1991).
  • Furst DE , WallisR, BroderM, BeenhouwerDO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum.36 , 159–167 (2006).
  • Morton NE , CollinsA. Tests and estimates of allelic association in complex inheritance. Proc. Natl Acad. Sci. USA95 , 11389–11393 (1998).
  • Plenge RM , BridgesSL Jr. Personalized medicine in rheumatoid arthritis: miles to go before we sleep. Arthritis Rheum.63 , 590–593 (2011).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.